Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.62 |
| ▸ | CDK2 | P24941 | 8/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.62 |
| ▸ | PRKCB | P05771 | 12/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111484 | 0.77 | PRKCB (0.63) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL13906194 | 0.76 | CCNA2 (0.81) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL13915354 | 0.75 | CDK2 (0.63) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL5428943 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL3457920 | 0.74 | CCNA2 (0.46) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL14522907 | 0.74 | PRKCB (0.62) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL6377596 | 0.73 | PRKCB (0.99) | PRKCB | |
| SCHEMBL3485260 | 0.73 | CDK2 (0.66) | CCNA2CDK2CCNA1PRKCB | |
| SCHEMBL6378511 | 0.72 | PRKCB (0.98) | PRKCB | |
| SCHEMBL6378721 | 0.72 | PRKCB (0.99) | PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575954-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-03 | — | — | EP | claimed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | claimed |
| EP-1575954-B1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-26 | — | — | US | disclosed |
| US-8557857-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-8557845-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-8481585-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-07-09 | — | — | US | disclosed |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-10 | — | — | US | disclosed |
| EP-2266987-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | Pfizer Italia S.r.l. (IT) | 2010-12-29 | — | — | EP | disclosed |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-26 | — | — | US | disclosed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | disclosed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | CCNA2 117/4885CDK2 3/4885CCNA1 41/4885 |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CCNA2 117/4885CDK2 3/4885CCNA1 41/4885 |
| US-20130012507-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CCNA2 117/4885CDK2 3/4885CCNA1 41/4885 |
| US-20090082346-A1 | Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors | CCNI, CDK1, CDK2 | CCNA2 117/4885CDK2 3/4885CCNA1 41/4885 |
| US-20130017170-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | CCNA2 117/4885CDK2 3/4885CCNA1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.